Square Pharmaceuticals PLCDSEBD: SQURPHARMA

SQURPHARMA: Net revenue grew 21.7% and net profit after tax rose 21.5% year-over-year in Q1 FY2025-26

· Issued by Square Pharmaceuticals PLC

Q1 FY2025-26 saw net revenue rise 21.7% year-over-year to Tk. 21.59 billion and net profit after tax up 21.5% to Tk. 7.40 billion. EPS increased to Tk. 8.35, with strong cash flow and asset growth, reflecting robust recovery and business momentum.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Square Pharmaceuticals PLC on 6ix

Earlier from Square Pharmaceuticals

Later from Square Pharmaceuticals

All Square Pharmaceuticals news releases